GentiBio

GentiBio engineers regulatory T-cells in novel biosynthetic ways to address serious unmet medical needs for auto-immunity, -inflammation and allergy patients.

[GentiBio @GentiBio]

Learn more about the POLARIS Study: https://t.co/vGJ9dyyKl5

[GentiBio @GentiBio]

Kicking off tomorrow, GentiBio joins the AAI Conference to present our latest research data and insights. For full event details, please visit the press release here: https://t.co/zd972dNAk9

#2026AAI #immunology #biotech #AmericanAssociationofImmunologists #Treg #CellTherapy

[GentiBio @GentiBio]

✔️Christopher Moore, Director, will be presenting “An Allogeneic CD19-Targeted Engineered Treg Approach for Treating B Cell-Mediated Autoimmune Diseases” on Saturday, April 18 (2:30 PM)

[GentiBio @GentiBio]

We are excited to be presenting at the upcoming #AAI2026 next week and connecting with colleagues across the immunology community. Our team will be sharing both seminar presentations and poster sessions highlighting our latest advances in engineered regulatory T cell therapies.

[GentiBio @GentiBio]

✔️ Victoria DeVault-Nelson, Associate Director, will be presenting “Comprehensive Biomarker Strategy to Monitor GNTI-122, an Engineered Regulatory T Cell Therapy in Clinical Development to Treat Type 1 Diabetes” on Saturday, April 18 (2:30 PM)

[GentiBio @GentiBio]

Read the full announcement: https://t.co/WpQqQv8OYr

[GentiBio @GentiBio]

GentiBio has successfully dosed the first participant in our clinical trial, the POLARIS Study, for adults recently diagnosed with Type 1 Diabetes (T1D). We are incredibly proud to announce this meaningful milestone for our team and community.

[GentiBio @GentiBio]

Learn more about the POLARIS Study: https://t.co/vGJ9dyyKl5

[GentiBio @GentiBio]

GentiBio announces preclinical data at #ESGCT showing antigen-specific engineered #Tregs suppressing pancreatic inflammation and potential utility for treatment and prevention of clinical type 1 #diabetes (#T1D)." Click here to learn more: https://t.co/QP8uKlFrbq

[GentiBio @GentiBio]

We’re thrilled to announce our collaboration with global leader @bmsnews to develop new engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with IBD. Read more here: https://t.co/zkMyRrGALu

[GentiBio @GentiBio]

Genti is happy to announce that Neely Mozaffarian, MD, PhD has joined as Chief Medical Officer. Please join us in welcoming Neely!
https://t.co/fYxUompR2y

[GentiBio @GentiBio]

We are excited to welcome our new CFO Chuck Silberstein to the team! https://t.co/It3X45xAEj

[GentiBio @GentiBio]

GentiBio is thrilled to share a perspective piece on how to succeed. Our CEO, Adel Nada, discusses, in order to succeed you need to prepare for failure and the importance of learning from mistakes. Enjoy! https://t.co/VyCSsiIk7o

[GentiBio @GentiBio]

GentiBio is excited to welcome 2022 and honored to be part of this list https://t.co/WgOunuAMsW

[GentiBio @GentiBio]

Congratulations to our fellow @NewEnglandVC #NEVYs21 Nominees –we're so proud to be nominated alongside this group of superheroes! December
2nd we will be at the @HOBBoston for the 9th Annual NEVY Awards, and we hope you’ll join us! https://t.co/fuxH3wPArB

[GentiBio @GentiBio]

Proud to be working with Seattle Children's in the Treg cell therapy space! @seattlechildren
https://t.co/sZHsioZDj1

[GentiBio @GentiBio]

Following the successful closing of a $157 million Series A, @GentiBio will continue to develop and advance its potential functional cure for #T1D to the clinic, alongside multiple other pipeline programs in chronic autoimmunity and autoinflammation. https://t.co/eIH9obyr7m